Table 1 Representative serum analytes (mean [SD]) for subjects receiving HICS or placebo treatment over 26 weeks
Change during study HICS | Change during study placebo | HICS versus placebo | |||||||
|---|---|---|---|---|---|---|---|---|---|
Direction of change | Basal | 26 wk | 26 wk versus basal p value | Basal | 26 wk | 26 wk versus basal p value | Fold change | q value | p value |
Sample number | n = 10 | n = 9 | n = 9 | n = 10 | n = 10 | n = 10 | |||
UP | |||||||||
α-MSH pg/ml | 3.7 [3.6] | 31.1 [35.8] | 0.0035 | 1.8 [0.9] | 2.2 [1.9] | 0.75 | 299.6 | 0 | 0.039 |
ACTH pg/ml | 1.9 [2.4] | 27.6 [42.3] | 0.0099 | 1.1 [1.1] | 1.0 [0.7] | 0.97 | 176.6 | 0 | 0.05 |
bFGF pg/ml | 3.4 [6.5] | 21.5 [21.9] | 0.0185 | 21.3 [43.3] | 23.6 [51.6] | 0.62 | 65 | 0 | 0.15 |
PIIINP ug/ml | 6.9 [3.8] | 15.4 [10.1] | 0.0002 | 5.3 [2.7] | 5.9 [2.7] | 0.62 | 14.6 | 20 | 0.012 |
DOWN | |||||||||
COMP ng/ml | 1.8 [1.1] | 1.4 [0.3] | 0.055 | 1.3 [0.5] | 1.4 [0.6] | 0.7 | −3.38 | 36 | 0.265 |
FRACT (CX3CL1) ng/ml | 3.7 [6.4 | 3.3 [6.1] | 0.108 | 1.1 [0.7] | 1.0 [0.6] | 0.79 | −6.1 | 43 | 0.318 |
CCL2 (MCP1) pg/ml | 262.3 [101.1] | 202.4 [132.0] | 0.239 | 280.6 [133.6] | 325.8 [225.9] | 0.293 | −0.5 | 36 | 0.121 |
TIMP2 ng/ml | 13.4 [1.9] | 13.0 [1.8] | 0.322 | 13.1 [1.8] | 13.9 [2.3] | 0.172 | −12.6 | 43 | 0.1044 |
TGFβ1 ng/ml | 29.4 [7.9] | 27.8 [4.3] | 0.901 | 26.4 [4.4] | 25.4 [10.4] | 0.385 | −3.8 | 43 | 0.601 |
Gro-α pg/ml | 35.0 [97.2] | 10.7 [17.1] | 0.076 | 3.6 [5.5] | 10.2 [15.1] | 0.939 | −2.3 | 36 | 0.206 |
IL6 pg/ml | 4.6 [9.7] | 1.4 [1.4] | 0.309 | 25.4 [69.5] | 30.6 [66.8] | 0.128 | −0.04 | 36 | 0.053 |